The abstract is read at the publisher; the summary is JClub's.
PI3K pathway alterations are frequent oncogenic drivers in estrogen receptor-positive breast cancer, and PI3K-targeted therapy is constrained by adaptive resistance and pathway reactivation.
- Why it matters: Targeting PI3K is limited by toxicity, signaling crosstalk, and compensatory mechanisms that make responses transient in estrogen receptor-positive disease.
- What they did: Advances in structural and functional characterization of PIK3CA mutations are enabling more selective PI3K inhibitors, including isoform-selective and emerging allosteric PI3Ka mutant-targeted compounds, alongside combination regimens with endocrine therapy and CDK4/6 inhibitors.
- The result: These strategies aim to improve the therapeutic index and counter adaptive resistance, while ongoing work optimizes combinations, predictive biomarkers, and treatment sequencing for more durable responses with less toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.